Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Objectives Immune factors determining clinical progression following HIV-1 infection remain unclear. The SPARTAC trial randomised 366 participants in primary HIV infection (PHI) to different short course therapies. The aim of this study was to investigate how early immune responses in PHI impacted clinical progression in SPARTAC. Design and Methods Participants with PHI recruited to the SPARTAC trial were sampled at enrolment, prior to commencing any therapy. HIV-1 specific CD4 and CD8 ELISpot responses were measured by gamma interferon ELISPOT. Immunological data were associated with baseline covariates and times to clinical progression using logistic regression, Kaplan-Meier plots, and Cox models. Results Making a CD4 T cell ELISpot response (n=119) at enrolment was associated with higher CD4 counts (p=0.02) and to some extent lower plasma HIV RNA (p=0.07). There was no correlation between the number of overlapping Gag CD8 T cell ELISpot responses (n=138) and plasma HIV-1 RNA viral load. Over a median follow-up of 2.9 years, baseline CD4 cell ELISpot responses (n=119) were associated with slower clinical progression (p=0.01; log-rank). Over a median of 3.1 years, there was no evidence for a survival advantage imposed by CD8 T cell immunity (p=0.82). Conclusions These data support a dominant protective role for CD4 T cell immunity in PHI compared with CD8 T cell responses, and are highly pertinent to HIV pathogenesis and vaccines, indicating that vaccine-induced CD4 responses may confer sustained benefit.

Type

Journal article

Journal

AIDS (In Press)

Publication Date

01/12/2013